Related Experiment Video

Updated: Jul 15, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Novel approaches to advanced breast cancer: bevacizumab and lapatinib

Erica L Mayer1, Nancy U Lin, Harold J Burstein

  • 1Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

Journal of the National Comprehensive Cancer Network : JNCCN
|April 19, 2007
PubMed

Insights

New breast cancer therapies, including anti-angiogenesis and anti-HER2 treatments, are advancing. This review focuses on bevacizumab and lapatinib for metastatic breast cancer, addressing integration and side effect management.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Emerging biological therapies are transforming breast cancer treatment paradigms.
  • Anti-angiogenesis and anti-HER2 therapies represent significant advancements in targeted treatment strategies.

Purpose of the Study:

  • To review recent progress in biological therapies for metastatic breast cancer.
  • To discuss the clinical integration and management of novel targeted agents like bevacizumab and lapatinib.

Main Methods:

  • Literature review of recent clinical studies and advancements.
  • Focus on anti-vascular endothelial growth factor (VEGF) antibody bevacizumab.
  • Focus on dual kinase inhibitor lapatinib.

Main Results:

  • Bevacizumab and lapatinib show promise as next-generation treatments for metastatic breast cancer.
  • Identified key questions regarding optimal use of these targeted agents in clinical practice.

Conclusions:

  • Bevacizumab and lapatinib are important new agents in metastatic breast cancer treatment.
  • Further research is needed to optimize integration, combination strategies, and side effect management for these novel therapies.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...